Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IG-002
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IG-002 addresses all forms of ABCA4-related retinopathies, a subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable (12-month) expression of human ABCA4 protein in adult porcine retinas.
Product Name : IG-002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : IG-002
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : ATPGroup
Deal Size : $75.0 million
Deal Type : Series A Financing
Details : Intergalactic’s non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA which relies on a cellfree manufacturing process; and 2) COMET, a clinically advanced, pulsed electric field focal gene therapy d...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 10, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : ATPGroup
Deal Size : $75.0 million
Deal Type : Series A Financing
Reset All
